NasdaqGS:GHHealthcare
Guardant Health (GH) Stock After New FDA Guardant360 CDx Approval Is There Still Upside In The Valuation
Guardant Health (GH) is back in focus after the U.S. FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS in HER2 mutant advanced non small cell lung cancer.
See our latest analysis for Guardant Health.
The FDA decision appears to have arrived on top of already strong momentum, with a 30 day share price return of 33.67% and a 1 year total shareholder return of 167.03%, suggesting sentiment has shifted rapidly in Guardant Health’s...